Table 51Summary of included studies. Comparison 50. Augmenting with buspirone versus continuing with antidepressant (+/− placebo)

StudyPopulationInterventionComparisonDetails of inadequate response/treatment resistanceComments

Appelberg 2001

RCT

Finland

N=113

Mean age (years): 44

Gender (% female): 63

Ethnicity (% BME): NR

Baseline severity: NR (more severe)

Buspirone 20-60mg/day + citalopram or fluoxetinePlacebo + citalopram or fluoxetineInadequate response (as judged by the psychiatrist in charge of treatment) to ≥ 6 weeks of treatment with fluoxetine (at a dose of ≥30mg/day for ≥4 weeks prior to inclusion) or citalopram (at a dose of ≥40mg/day for ≥4 weeks prior to inclusion)

Treatment length (weeks): 6

Outcomes:

  • Response

Fang 2011

RCT

China

N=91

Mean age (years): NR

Gender (% female): NR

Ethnicity (% BME): NR

Baseline severity: NR (more severe)

Buspirone 30mg/day + paroxetineParoxetine 20mg/dayTRD: Inadequate response to ≥2 adequate treatments from different classes of antidepressants in the current depressive episode (adequate dosages of antidepressants with at least 3-month duration) determined through medical records and/or prospective treatment

Treatment length (weeks): 8

Outcomes:

  • Remission
  • Response
  • Quality of life physical component score
  • Quality of life mental component score

BME: black and minority ethnic; NR: not reported; RCT: randomised controlled trial; TRD: treatment-resistant depression

From: Further-line treatment

Cover of Further-line treatment
Further-line treatment: Depression in adults: Evidence review D.
NICE Guideline, No. 222.
Copyright © NICE 2022.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.